Mast Therapeutics (MSTX) Shares See Strong Trading Amid Corp. Overview

Mast Therapeutics (NYSE: MSTX) shares are up markedly as the company filed its Corporate Overview today.

In part, Mast Therapeutics offering the following overview:

Cash/investments at 8/31/2016 were $30.3 million.

• $10.6 million in principal debt payments made on Sept. & Oct.
• Outstanding principal debt balance of $3.7 million

Estimate operating expenses for 2017 are about $8 to $9 million

The company is focused on clinical development of AIR001 for HFpEF

• Supporting three investigator-sponsored Phase 2 clinical studies at prestigious research institutions
• Interim results from HFpEF-PH expected in Q416
• Results from 100-patient INDIE study expected in Q417

MSTX is actively evaluating partnering and licensing opportunities.

The Overview is embedded below. MSTX shares are up 7.7 percent.

You May Also Be Interested In

• Visa (V) stock rises as Q2 earnings, revenue come ahead of estimates
• Texas Instruments (TXN) jumps on first above-consensus guide in seven years
• Wolfspeed pops as activist investor urges firm to consider options, including sale